Low vitamin D in patients with nasal polyps negatively correlated with several markers, including Lund-Mackay and total nasal ...

AZ is hoping that Fasenra (benralizumab) could join rival drugs from Sanofi/Regeneron and GlaxoSmithKline as approved therapies for chronic rhinosinusitis with nasal polyps (CRSwNP) that have been ...

The China National Medical Products Administration (NMPA) has approved GSK’s Nucala (mepolizumab) as an add-on treatment with intranasal corticosteroids to treat chronic rhinosinusitis with nasal ...

GSK's experimental IL-5 inhibitor depemokimab has shown its potential in a pair of phase 3 trials in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The company said this morning ...

Nucala (mepolizumab), has been approved in China for treating adults with chronic rhinosinusitis with nasal polyps (CRSwNP), a condition affecting 30 million people in the country. This approval ...

GSK's Nucala approved in China for CRSwNP, affecting 1/3 of 107 million sinusitis patients; third IL-5 condition indication in the region. Phase 3 trial shows Nucala reduces COPD exacerbations ...

CRSwNP, for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. It is estimated that about 107 million people in China suffer from chronic sinusitis ...

A 2023 article notes that they most commonly develop in those with chronic rhinosinusitis, which has resulted in the term chronic rhinosinusitis with nasal polyposis (CRSwNP). Other associations ...

GSK (NYSE:GSK) has received Chinese regulatory approval for its drug Nucala, also known as mepolizumab, for the treatment of adults with inadequately controlled chronic rhinosinusitis with nasal ...

The China National Medical Products Administration (NMPA) has approved GSK’s Nucala (mepolizumab) as an add-on treatment with intranasal corticosteroids to treat chronic rhinosinusitis with ...

Also Read: GSK Raises Prospects For Withdrawn Blood Cancer Drug Blenrep To Return To US Market – Here's Why People with CRSwNP experience symptoms such as nasal obstruction, loss of smell ...

On Friday, the China National Medical Products Administration approved GSK plc (NYSE:GSK) Nucala (mepolizumab) as an add-on therapy with intranasal corticosteroids for adult patients with chronic ...